The $1.9 Billion Bet: Chiesi Acquires KalVista, Redefining Rare Disease Value

Related Articles

Amicus Therapeutics: A Rare Disease Gem Acquired

6 months ago

What Does FDA Orphan Drug Designation Mean for Cure Rare Disease's SCA3 Treatment

5 months ago

Is the Satellite-to-Cell Race Redefining Telecom Connectivity

6 months ago

How is AI Redefining Customer Service and What Does it Mean for Businesses

6 months ago

Category

You may also like

Stock News•1 week ago

BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans

BridgeBio reached a voluntary U.S. government agreement to expand Medicaid access and lower drug costs for its marketed rare-disease medicine, aiming to improve affordability without undermining innov...

BBIO

Share

Stock News•2 weeks ago

Palvella Therapeutics: First Approval Could Unlock A Rare-Disease Commercial Flywheel

Palvella Therapeutics advanced QTORIN rapamycin toward a first approval, with positive Phase 3 SELVA data and a rolling NDA submission underway. A $230M equity raise funds commercialization and pipeli...

PVLA

Share

Stock News•1 months ago

Italy's Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst

Angelini Pharma completed its $4.1B state-backed acquisition of Catalyst Pharmaceuticals, a U.S. rare-disease drug maker, on Thursday.

CPRX

Share